Stability of alteplase in presence of cavitation.
Several experimental studies have demonstrated that ultrasound (US) can accelerate enzymatic fibrinolysis and this effect is further enhanced in the presence of ultrasound contrast agents (UCA). Although UCA have been shown to be safe when administered to ischemic stroke patients, safety information of these agents in the thrombolysis setting is limited. Therefore, in this study we investigated potential adverse effects of acoustic cavitation generated by UCA on alteplase (t-PA), the drug used for treatment of ischemic stroke patients. A volume of 0.9 mL of alteplase was dispensed into a custom-made polyester sample tube. For treatments in the presence or absence of cavitation either 0.1 mL Optison or phosphate buffer saline was combined with alteplase. Three independent samples of each treatment group were exposed to ultrasound of 2 MHz frequency at three different peak negative acoustic pressures of 0.5, 1.7, and 3.5 MPa for a duration of 60 min. All treatments were carried out in a cavitation detection system which was used to insonify the samples and record acoustic emissions generated within the sample. After ultrasound exposure, the treated samples and three untreated drug samples were tested for their enzymatic activity using a chromogenic substrate. The insonified samples containing Optison demonstrated cavitational activity proportional to acoustic pressure. No significant cavitation activity was observed in the absence of Optison. Enzymatic activity of alteplase in both insonified groups was comparable to that in the control group. These tests demonstrated that exposure of alteplase to 60 min of 2 MHz ultrasound at acoustic pressures ranging from 0.5 MPa to 3.5 MPa, in the presence or absence of Optison had no adverse effects on the stability of this therapeutic compound.
Soltani
Azita
A
EKOS Corporation, 11911 North Creek Parkway South, Bothell, WA 98011, USA. asoltani@ekoscorp.com
Prokop
Adrian F
AF
Vaezy
Sara
S
D000418:Albumins / Q000737:chemistry* / Q000528:radiation effects*; D004307:Dose-Response Relationship, Radiation; D004355:Drug Stability; D004789:Enzyme Activation / Q000528:radiation effects; D004795:Enzyme Stability / Q000528:radiation effects; D005343:Fibrinolytic Agents / Q000737:chemistry / Q000528:radiation effects; D005466:Fluorocarbons / Q000737:chemistry* / Q000528:radiation effects*; D011829:Radiation Dosage; D013010:Sonication; D010959:Tissue Plasminogen Activator / Q000737:chemistry* / Q000528:radiation effects*
D000418:Albumins; C099458:FS 069; D005343:Fibrinolytic Agents; D005466:Fluorocarbons; D010959:Tissue Plasminogen Activator